The story of Viagra and its originator, copyright, presents a fascinating picture for cautious investors. While the blockbuster drug initially fueled enormous revenues , its protection has ended, leading to rival options flooding the landscape . This reduction in cost presents a significant challenge for copyright and any portfolio considering a… Read More